Haemonetics Corporation (HAE): Business Model Canvas [Jan-2025 Mise à jour]

Dans le paysage complexe de la technologie médicale, Haemonetics Corporation (HAE) apparaît comme une force pionnière, transformant la gestion du sang à travers des solutions innovantes qui révolutionnent la prestation des soins de santé. En tirant stratégiquement les technologies médicales avancées et les partenariats mondiaux, cette organisation dynamique a conçu un modèle commercial sophistiqué qui relève des défis critiques dans la collecte de sang, le traitement et le soutien chirurgical. Leur approche complète améliore non seulement la sécurité des patients, mais entraîne également des améliorations significatives des procédures médicales dans divers environnements de soins de santé dans le monde.

Haemonetics Corporation (HAE) - Modèle commercial: partenariats clés

Alliances stratégiques avec les hôpitaux et les centres sanguins du monde

Haemonetics Corporation maintient des partenariats stratégiques avec plus de 3 500 centres sanguins et hôpitaux dans le monde. En 2024, ces partenariats couvrent les régions clés, notamment:

Région	Nombre de partenariats	Couverture du marché
Amérique du Nord	1,250	45% de pénétration du marché
Europe	850	35% de pénétration du marché
Asie-Pacifique	750	25% de pénétration du marché
l'Amérique latine	400	15% de pénétration du marché
Moyen-Orient / Afrique	250	10% de pénétration du marché

Partenariats avec les fabricants d'appareils médicaux

Haemonetics collabore avec plusieurs fabricants d'appareils médicaux pour améliorer les capacités technologiques:

• Thermo Fisher Scientific - Intégration de la technologie de collecte de sang
• Becton Dickinson - Systèmes de traitement du sang automatisé
• Terumo Corporation - Équipement de collecte de plasma

Collaboration avec les innovateurs de la technologie des soins de santé

Les partenariats technologiques clés comprennent:

Partenaire	Focus technologique	Montant d'investissement
IBM Watson Health	Gestion du sang dirigée par l'IA	12,5 millions de dollars
Google Cloud Healthcare	Plateforme d'analyse de données	8,3 millions de dollars
Microsoft Healthcare	Infrastructure cloud	6,7 millions de dollars

Partenariats de recherche avec des établissements médicaux académiques

Haemonetics maintient des collaborations de recherche avec les principaux établissements universitaires:

• Harvard Medical School - Blood Transfusion Technologies
• Centre médical de l'Université de Stanford - Traitement du sang automatisé
• Université Johns Hopkins - Recherche d'hémostase
• Clinique Mayo - Innovations de gestion du sang

Investissement total de partenariat de recherche en 2024: 24,6 millions de dollars

Haemonetics Corporation (HAE) - Modèle d'entreprise: activités clés

Conception et fabrication de dispositifs médicaux

Haemonetics Corporation a investi 79,4 millions de dollars dans les frais de recherche et de développement au cours de l'exercice 2023. La société exploite des installations de fabrication dans plusieurs endroits, notamment le Massachusetts, les États-Unis et l'Irlande.

Usine de fabrication	Emplacement	Ligne de produit primaire
Installation de Braintree	Massachusetts, États-Unis	Systèmes de collecte de sang
Épée	Irlande	Équipement de collecte de plasma

Développement de la technologie de gestion du sang

Haemonetics détient 139 brevets actifs en 2023, en se concentrant sur les technologies avancées de gestion du sang.

• Technologie de collecte de plasma
• Systèmes de traitement du sang automatisé
• Solutions diagnostiques avancées

Création de logiciels médicaux et de solution de diagnostic

La société a généré 241,6 millions de dollars de revenus de solutions logicielles et de diagnostic au cours de l'exercice 2023.

Catégorie de logiciels	Contribution des revenus
Logiciel de gestion de la banque sanguine	87,3 millions de dollars
Systèmes de suivi de diagnostic	154,3 millions de dollars

Ventes mondiales et distribution des systèmes de collecte de sang

Haemonetics opère dans plus de 50 pays, un réseau de vente mondial générant 1,02 milliard de dollars de revenus totaux pour l'exercice 2023.

Région géographique	Revenus de vente
Amérique du Nord	512,4 millions de dollars
Europe	287,6 millions de dollars
Asie-Pacifique	220 millions de dollars

Recherche continue et innovation de produit

Haemonetics a employé 619 professionnels de la recherche et du développement en 2023, ce qui représente 12,4% de la main-d'œuvre totale.

• Investissement annuel de R&D: 79,4 millions de dollars
• Lancements de nouveaux produits: 7 innovations majeures en 2023
• Cycle d'amélioration de la technologie: 18-24 mois

Haemonetics Corporation (HAE) - Modèle d'entreprise: Ressources clés

Technologie médicale avancée et brevets

Haemonetics Corporation détient 374 brevets actifs en 2023. L'investissement total de R&D en 2022 était de 145,3 millions de dollars, ce qui représente 8,2% du total des revenus de l'entreprise.

Catégorie de brevet	Nombre de brevets actifs
Technologie de collecte de sang	187
Aphérèse thérapeutique	92
Traitement du plasma	95

Équipes d'ingénierie et de R&D spécialisées

Haemonetics emploie 1 247 professionnels de la recherche et de l'ingénierie dans le monde au quatrième trimestre 2023.

• Centres mondiaux de R&D situés aux États-Unis, en Irlande et en Chine
• Expérience d'ingénierie moyenne: 12,5 ans
• Tapisseurs de doctorat: 24% de la main-d'œuvre de la R&D

Installations de fabrication

Haemonetics exploite 7 installations de fabrication dans 5 pays.

Emplacement	Type d'installation
Braintree, Massachusetts, USA	Siège mondial principal et fabrication
Dublin, Irlande	Centre de fabrication européenne
Shanghai, Chine	Centre de fabrication asiatique

Portefeuille de propriété intellectuelle

Évaluation totale de la propriété intellectuelle estimée à 672 millions de dollars en 2023.

• Protection des brevets dans 42 pays
• Inscriptions de la marque: 156
• Cycle de vie moyen des brevets: 15-17 ans

Capacités de recherche clinique

Le budget de la recherche clinique pour 2023 était de 87,6 millions de dollars.

Domaine de mise au point de recherche	Essais cliniques actifs
Technologies de collecte de sang	18
Aphérèse thérapeutique	12
Fractionnement du plasma	7

Haemonetics Corporation (HAE) - Modèle d'entreprise: propositions de valeur

Solutions avancées de gestion du sang

Haemonetics Corporation génère 1,02 milliard de dollars de revenus annuels (2023 exercices). Les solutions avancées de gestion du sang de l'entreprise comprennent:

• Systèmes de collecte de sang automatisés
• Technologies de fractionnement du plasma
• Plateformes de traitement de la thérapie cellulaire

Catégorie de produits	Contribution des revenus	Part de marché
Technologies de collecte de sang	412 millions de dollars	38% de part de marché mondiale
Systèmes de gestion du plasma	328 millions de dollars	45% de part de marché mondiale
Solutions de thérapie cellulaire	280 millions de dollars	29% de part de marché mondiale

Technologies efficaces de collecte et de traitement du sang

Haemonetics développe des équipements de gestion du sang de précision avec des spécifications suivantes:

• MCS + Système de collecte de plasma Vitesse de traitement: 800 ml par heure
• Précision totale de la collecte de sang: 99,7%
• Efficacité automatisée de collecte des plaquettes: taux de récupération de 92%

Amélioration de la sécurité des patients et des résultats chirurgicaux

Les technologies médicales de l'entreprise démontrent:

Métrique de sécurité	Performance
Réduction de l'infection	37% inférieur par rapport aux méthodes traditionnelles
Minimisation chirurgicale de la perte de sang	Réduit la perte de sang moyenne de 45%
Risque de transfusion du patient	Diminue de 28%

Technologies de dispositifs médicaux innovants

Investissement en R&D: 124 millions de dollars (2023), représentant 12,1% des revenus totaux.

• 5 nouveaux brevets de dispositifs médicaux déposés en 2023
• 3 désignations de périphériques de percée de la FDA
• 2 Actions internationales de l'innovation en technologie médicale

Systèmes de gestion complète de l'hémostase

Positionnement du marché pour la gestion de l'hémostase:

Gamme de produits	Pénétration mondiale du marché	Taux de croissance annuel
Analyseur d'hémostase TEG 6S	42 pays	18.5%
Solutions complètes de gestion des saignements	37 systèmes de soins de santé	15.3%

Haemonetics Corporation (HAE) - Modèle d'entreprise: relations clients

Soutien direct des ventes pour les institutions médicales

Haemonetics maintient une force de vente dédiée de 387 représentants des ventes directes à partir de 2023, ciblant les hôpitaux, les banques de sang et les centres médicaux dans le monde.

Canal de vente	Nombre de représentants	Couverture géographique
Amérique du Nord	156	États-Unis et Canada
Europe	89	Union européenne et Royaume-Uni
Asie-Pacifique	72	Chine, Japon, Australie
Reste du monde	70	Amérique latine, Moyen-Orient

Services de consultation technique

Haemonetics fournit une consultation technique spécialisée par le biais de 142 experts techniques dédiés dans différentes régions.

• Temps de réponse moyen: 2,5 heures
• Disponibilité du support technique 24/7
• Équipe de support multilingue

Support de formation et de mise en œuvre

L'entreprise propose des programmes de formation complets avec 673 spécialistes de formation certifiés dans le monde.

Type de formation	Sessions de formation annuelles	Participants moyens par session
Formation sur place	1,245	12-15
Formation virtuelle	2,387	25-30
Certification des produits	876	8-10

Service client et assistance technique en cours

Haemonetics maintient une équipe de service client de 256 professionnels avec une note de satisfaction client moyenne de 4,7 / 5.

• Temps de résolution du problème moyen: 4,2 heures
• Taux de rétention de la clientèle: 94,3%
• Volume d'interaction client annuelle: 127 500 billets de support

Plateforme numérique pour la gestion des produits et le support

Les statistiques de plate-forme numérique pour 2023 révèlent un engagement important des utilisateurs:

Métrique de la plate-forme	Valeur
Utilisateurs enregistrés	18,750
Utilisateurs actifs mensuels	12,400
Interactions annuelles sur la plate-forme	436,000
Taux de résolution en libre-service	62%

Haemonetics Corporation (HAE) - Modèle d'entreprise: canaux

Force de vente directe

Haemonetics maintient une force de vente directe dédiée de 374 représentants commerciaux à partir de 2023, ciblant les établissements de santé dans le monde.

Métriques du canal de vente	2023 données
Représentants totaux des ventes directes	374
Couverture géographique	Plus de 50 pays
Cycle de vente moyen	6-9 mois

Distributeurs d'équipement médical

Haemonetics s'associe à 127 distributeurs d'équipements médicaux dans différentes régions.

• Réseaux de distribution de partenaires en Amérique du Nord
• Canaux de distribution des équipements médicaux européens
• Distributeurs régionaux d'Asie-Pacifique

Plateformes de vente en ligne

Les canaux de vente numériques ont généré 87,3 millions de dollars de revenus en 2023.

Plate-forme en ligne	Revenus de 2023
Site Web de l'entreprise	42,6 millions de dollars
Market numérique B2B	44,7 millions de dollars

Expositions de la conférence médicale

Haemonetics a participé à 43 conférences médicales internationales en 2023, générant environ 15,2 millions de dollars en ventes directes.

Canaux de marketing numérique et de commerce électronique

Les dépenses de marketing numérique ont atteint 6,7 millions de dollars en 2023, les canaux de commerce électronique, ce qui contribue à 22,5 millions de dollars de revenus.

Métriques du marketing numérique	2023 données
Dépenses marketing	6,7 millions de dollars
Revenus de commerce électronique	22,5 millions de dollars
Taux de conversion numérique	3.2%

Haemonetics Corporation (HAE) - Modèle d'entreprise: segments de clientèle

Hôpitaux et centres chirurgicaux

En 2024, Haemonetics dessert environ 4 300 hôpitaux dans le monde. La rupture du segment de la clientèle révèle:

Type d'hôpital	Pénétration du marché	Procédures annuelles
Grands hôpitaux d'enseignement	62%	1 850 000 procédures de gestion du sang
Hôpitaux communautaires	38%	1 100 000 procédures de gestion du sang

Banques de sang et centres de dons

Haemonetics soutient 1 250 centres de collecte de sang dans le monde avec des équipements spécialisés.

• Amérique du Nord: 450 banques de sang
• Europe: 380 banques de sang
• Asie-Pacifique: 320 banques de sang
• Amérique latine: 100 banques de sang

Systèmes de soins de santé et réseaux

La société dessert 85 réseaux de soins de santé intégrés représentant 2 700 établissements de santé.

Taille du réseau	Nombre de réseaux	Total des installations
Grands réseaux (50+ installations)	22	1 650 installations
Réseaux moyens (10-49 installations)	63	1 050 installations

Institutions de recherche médicale

Haemonetics soutient 340 institutions de recherche médicale dans le monde.

• Centres de recherche universitaire: 210
• Institutions de recherche privées: 95
• Installations de recherche gouvernementales: 35

Fournisseurs de services médicaux d'urgence

La société dessert 1 100 organisations de services médicaux d'urgence dans différentes régions.

Région	Organisations EMS	Interventions annuelles de gestion du sang
États-Unis	650	475,000
Union européenne	280	210,000
Autres régions	170	125,000

Haemonetics Corporation (HAE) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2023, Haemonetics Corporation a investi 87,3 millions de dollars dans les frais de recherche et développement, ce qui représente 8,4% du total des revenus de l'entreprise.

Exercice fiscal	Investissement en R&D	Pourcentage de revenus
2023	87,3 millions de dollars	8.4%
2022	79,6 millions de dollars	7.9%

Frais de fabrication et de production

Les coûts de fabrication totaux pour les haémonétiques en 2023 étaient de 312,5 millions de dollars, avec des catégories de dépenses clés, notamment:

• Coûts de matériel direct: 156,2 millions de dollars
• Coûts de main-d'œuvre directes: 84,7 millions de dollars
• Fabrication des frais généraux: 71,6 millions de dollars

Opérations mondiales de vente et de marketing

Les frais de vente et de marketing pour Haemonetics au cours de l'exercice 2023 ont totalisé 203,4 millions de dollars, ce qui représente 19,6% des revenus totaux.

Région géographique	Dépenses de marketing	Pourcentage du budget des ventes
Amérique du Nord	112,8 millions de dollars	55.4%
Europe	56,9 millions de dollars	28%
Asie-Pacifique	33,7 millions de dollars	16.6%

Coûts de conformité réglementaire

Haemonetics a dépensé 45,2 millions de dollars pour la conformité réglementaire et l'assurance qualité en 2023, ce qui comprend:

• Conformité de la FDA: 18,6 millions de dollars
• Normes réglementaires internationales: 22,4 millions de dollars
• Systèmes de gestion de la qualité: 4,2 millions de dollars

Maintenance des infrastructures technologiques

Les coûts de maintenance de la technologie et de l'infrastructure informatique pour Haemonetics en 2023 étaient de 62,5 millions de dollars, décomposés comme suit:

• Infrastructure matérielle: 22,3 millions de dollars
• Licence et mises à jour du logiciel: 18,7 millions de dollars
• Systèmes de cybersécurité: 14,5 millions de dollars
• Services de cloud computing: 7 millions de dollars

Haemonetics Corporation (HAE) - Modèle d'entreprise: Strots de revenus

Ventes de dispositifs médicaux

Haemonetics Corporation a déclaré un chiffre d'affaires total de 1,02 milliard de dollars pour l'exercice 2023. Les ventes de dispositifs médicaux ont spécifiquement représenté 612,4 millions de dollars.

Catégorie de produits	Revenus ($ m)	Pourcentage du total
Systèmes de collecte de plasma	287.6	47%
Automation du centre sanguin	164.3	27%
Solutions chirurgicales à l'hôpital	160.5	26%

Contrats de maintenance des équipements récurrents

Les revenus des contrats de maintenance pour 2023 ont totalisé 87,3 millions de dollars, ce qui représente 8,6% du total des revenus de l'entreprise.

Revenus de produits consommables

Les ventes de produits consommables ont atteint 276,5 millions de dollars au cours de l'exercice 2023.

• Kits de collecte de sang jetables: 142,7 millions de dollars
• Disposables médicaux spécialisés: 133,8 millions de dollars

Licence de logiciels et de technologie

Les revenus des licences technologiques étaient de 24,6 millions de dollars en 2023.

Solutions mondiales de marché des soins de santé

Région géographique	Revenus ($ m)	Taux de croissance
Amérique du Nord	612.0	5.3%
Europe	246.5	3.7%
Asie-Pacifique	161.5	6.2%

Haemonetics Corporation (HAE) - Canvas Business Model: Value Propositions

You're looking at how Haemonetics Corporation delivers tangible value across its core markets as of late 2025. It's not just about selling devices; it's about measurable improvements in yield, patient safety, and hospital economics. Here's the breakdown of what they promise to deliver to their distinct customer segments.

Optimizing plasma center operations and increasing plasma yield via NexSys technology

For plasma collection centers, the value proposition centers on maximizing the most critical input: plasma volume per donor. The NexSys PCS platform, especially with Persona Technology, is central to this. This proprietary, donor-tailored solution moves beyond the old weight-only nomogram by using body mass index and hematocrit to customize collection targets. This personalization is clinically shown to yield an average of +9% to 12% more plasma per donation, based on a large, multicenter, randomized controlled trial involving 3,443 donors. This directly translates to cost-efficient output for centers, which is crucial since the Plasma segment represented 39.3% of Haemonetics Corporation's total revenue in fiscal 2025. Furthermore, the integration with NexLynk DMS donor management software has historically delivered a 16-minute reduction in donor door-to-door time, enhancing productivity.

Advancing patient care and enhancing outcomes in the surgical suite and hospital

In the Hospital segment, which accounted for 41.5% of fiscal 2025 revenue, the focus shifts to procedural efficiency and patient safety. Haemonetics Corporation's Interventional Technologies, which saw Q4 FY2025 revenue growth of +21.2% year-over-year for Interventional Technologies (including VASCADE MVP/XL), promise better outcomes. The company's overall Hospital segment showed strong reported revenue growth of 30.7% in Q1 FY2025 and contributed to the company's total Net Revenues of $1,360.8 million for FY2025. The value here is tied to improving metrics that drive economic benefits for treatment facilities.

Providing interventional technologies like VASCADE for vascular closure

Specifically within interventional cardiology and electrophysiology, the VASCADE family of Vascular Closure products offers a catheter-based delivery system that leverages collagen's natural clot-inducing properties. This novel design is marketed to significantly reduce access site complications compared to manual compression. A key differentiator is that the VASCADE MVP device was the first vascular closure device to receive an FDA indication for same-day discharge following atrial fibrillation ablation. This capability directly supports hospital throughput and reduces length-of-stay costs, a significant economic driver for the Hospital segment.

Offering esophageal protection with the EnsoETM device (from Attune Medical acquisition)

Following the acquisition of Attune Medical in fiscal 2025, Haemonetics Corporation integrated esophageal protection technology, notably the EnsoETM device, into its Hospital portfolio. While specific revenue contribution for EnsoETM isn't broken out, its inclusion strengthens the value proposition in the operating room and procedural areas by addressing patient safety during procedures requiring esophageal access or monitoring. This acquisition bolsters the Hospital segment, which achieved $147.9 million in revenue in Q4 FY2025. The overall adjusted operating margin improvement to 26.7% in Q2 FY2026 suggests successful integration and focus on higher-margin technologies.

Improving blood safety and operational efficiency for blood collection groups

For Blood Center customers, who contributed 19.2% of FY2025 revenue, the value proposition is about streamlined compliance and reduced operational friction. The NexSys PCS system, with its automated procedure programming and enforced documentation protocols, helps improve quality and compliance, simplifying audit support. This focus on operational excellence is set against a challenging backdrop, as the Blood Center segment saw a reported revenue decline of (21.7)% in Q1 FY2026, though management is focused on driving margin expansion, with an overall company adjusted gross margin reaching 60.5% in Q2 FY2026.

You can see the segment contribution and recent performance in the table below:

Segment	FY 2025 Revenue Contribution	Q4 FY2025 Revenue	Q1 FY2026 Reported Revenue Change (YoY)
Hospital	41.5%	$147.9M	+4.2%
Plasma	39.3%	Not Separately Listed	(4.4)%
Blood Center	19.2%	Not Separately Listed	(21.7)%

The company's overall financial health supports these value promises, evidenced by a fiscal 2025 Net Income of $167.7 million and a diluted EPS of $3.31. For the more recent Q2 FY2026, adjusted EPS was $1.27, up 13% year-over-year, showing profitability is being maintained even as the company navigates portfolio transitions.

• Persona Technology: Average plasma yield increase of 9% to 12% per donation.
• VASCADE MVP: First device with FDA indication for same-day discharge post-AFib ablation.
• FY 2025 Total Net Revenues: $1,360.8 million.
• Q4 FY2025 Adjusted Gross Margin: 60.2%.
• Q2 FY2026 Adjusted Operating Margin Guidance: 26% to 27%.

Haemonetics Corporation (HAE) - Canvas Business Model: Customer Relationships

You're looking at how Haemonetics Corporation (HAE) manages the critical link between its innovative medical devices and the healthcare providers who use them. This relationship is deeply embedded in service and long-term commitment, especially given the high-stakes nature of blood and plasma management.

Dedicated direct sales force and clinical specialists for high-touch customer support.

Haemonetics Corporation doesn't just ship equipment; they deploy a dedicated, high-touch support structure. They market and sell their products across approximately 95 countries using their own direct sales force, which includes full-time sales representatives and clinical specialists. This is complemented by independent distributors operating in about 90 countries. This structure ensures that the primary decision-makers within biopharmaceutical companies, blood collection groups, independent blood centers, and hospitals receive focused attention. To be fair, this level of support is necessary when dealing with complex, life-impacting technology.

The customer base shows a degree of concentration, but not over-reliance on any single entity as of the last full fiscal year:

Metric	Fiscal Year 2025 Data
Top Ten Customers' Share of Net Revenues	42%
Largest Single Customer Share of Consolidated Revenues	Less than 10%
Plasma Segment Customers > 10% of Segment Revenue	Four customers

Long-term supply agreements for automated systems and recurring disposables.

A core element of the relationship is locking in recurring revenue through agreements tied to the automated systems they install. For instance, a key supply agreement with CSL was amended to extend through December 2025. Under that non-exclusive agreement, CSL had a minimum purchase commitment of approximately $85 million in fiscal 2025. This disposable stream is the engine for the Plasma business, which represented 43.2% of total revenue in fiscal 2024. Still, you need to watch the transition; the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement was specifically excluded when calculating certain Q1 fiscal 2026 organic revenue growth figures, showing how these agreements shape near-term comparisons. The total company revenue for the fiscal year ending March 29, 2025, was $1.36B.

Customer collaborations for new product development and protocol enhancement.

Haemonetics Corporation actively seeks input to drive innovation, viewing customers as partners in development. This collaborative approach is cited as an important part of their technical strength and competitive advantage. These engagements directly feed the R&D pipeline:

• Provide ideas for new products and applications.
• Help enhance existing operational protocols.
• Serve as objective evaluation and expert opinion sites.
• Offer potential test sites for new technology.

Technical support and device servicing provided by regional support teams.

The relationship extends well beyond the initial sale and into the operational life of the equipment. Regional support teams are responsible for providing necessary technical support and device servicing. This is crucial for maintaining uptime on critical systems like the NexSys PCS® and PCS2® plasmapheresis equipment. For their U.S. Plasma customers, Haemonetics provides ongoing support for both the NexSys PCS devices and the NexLynk DMS donor management software.

High-volume, transactional sales of disposables, especially in the Plasma segment.

The transactional component is driven by the consumables needed for daily operations. While the Plasma segment is a major revenue contributor, its performance can fluctuate. For example, Plasma revenue in the first quarter of fiscal 2026 was $129.9 million, a decrease of 4.4% year-over-year. This contrasts with the Blood Center segment, which saw a 21.7% reported revenue decrease in Q1 FY2026, partly due to the divestiture of its Whole Blood business in January 2025. The Hospital unit, however, showed growth, with Q1 FY2026 revenue at $139.7 million, up 4.2%.

Finance: draft 13-week cash view by Friday.

Haemonetics Corporation (HAE) - Canvas Business Model: Channels

You're looking at how Haemonetics Corporation gets its medical technology and software into the hands of plasma collectors and hospitals. The reach is definitely global, relying on a mix of internal muscle and external partners.

Haemonetics Corporation markets and sells its products in approximately 95 countries globally. This extensive reach is supported by its own direct sales force, which includes full-time sales representatives, alongside a network of external partners.

The company relies on independent distributors and agents to cover a significant portion of this international footprint, specifically operating in approximately 90 countries globally as of the fiscal 2025 reporting period. For context, the Hospital business unit alone accounted for 41.5% of total net revenues in fiscal 2025, which totaled $1,360,824 thousand for the year.

Channel Component	Scope/Metric	Associated Fiscal 2025 Data Point
Total Countries of Market Presence	Approximately 95 countries	Total Net Revenues: $1,360,824 thousand
Independent Distributor Reach	Approximately 90 countries	Plasma Revenue: $535,431 thousand
Direct Sales Force Coverage	Key markets, including full-time representatives	Total Employees: 3,023

The delivery of value, especially in the Plasma segment, is heavily supported by integrated information technology platforms. These digital tools help plasma customers manage their donors, operations, and supply chain. Software products like the NexLynk DMS® donor management system and Donor360® tools automate key processes, from donor qualification to unit release.

These systems provide tangible operational data, which is a key part of the channel experience. Facilities use built-in reporting tools for supply chain equipment performance metrics, helping them manage processes across the entire plasma supply chain. This digital integration is crucial for maintaining high quality and compliance support.

To ensure customers get the most out of the complex hardware and software, Haemonetics Corporation deploys specialized personnel. This includes clinical specialists who provide on-site training and implementation support. This hands-on approach helps customers optimize their plasma collections and supports the transition to newer technologies like the NexSys PCS® device.

• Direct sales force targets primary decision-makers in customer organizations.
• Clinical specialists offer on-site training for device interfaces and software.
• IT platforms automate data capture, minimizing manual entry for traceability.
• Plasma revenue saw a 6.0% decrease in fiscal 2025 compared to fiscal 2024.

Finance: draft 13-week cash view by Friday.

Haemonetics Corporation (HAE) - Canvas Business Model: Customer Segments

You're looking at the core customer base for Haemonetics Corporation as of late 2025. Honestly, the customer concentration data tells a clear story about where the money is coming from right now.

The structure of Haemonetics Corporation's business is built around three primary operational segments, which directly map to your listed customer types. For fiscal year 2025, the total net revenues hit $1,360.8 million. The distribution across these customer-implied segments is what you need to focus on for near-term risk assessment.

Here's the quick math on how those segments-and thus, their corresponding customer groups-contributed to the top line in FY2025:

Customer Group Proxy (Segment)	FY2025 Revenue Contribution
Hospital (Surgical Suite, Transfusion Services)	41.5%
Plasma (Biopharmaceutical companies and large plasma fractionators)	39.3%
Blood Center (Independent blood centers and blood collection groups)	19.2%

The Hospital segment, which includes Interventional and Blood Management Technologies, was the largest revenue driver for Haemonetics Corporation in fiscal 2025. This segment serves hospitals and hospital service providers, and its growth was a key factor in the company's overall performance that year.

When you look at the overall customer base, concentration risk is definitely present, though it has slightly improved from prior years. In fiscal 2025, Haemonetics Corporation's ten largest customers accounted for approximately 42% of net revenues. To be fair, that's down from 48% in both fiscal 2024 and fiscal 2023. Still, this level of dependence means any disruption with a few key accounts is defintely material.

You should note the specifics around that concentration:

• No single customer represented greater than 10% of total net revenues in fiscal 2025.
• For the Plasma segment, four customers each accounted for greater than 10% of that segment's net revenues.
• For the Blood Center segment, two customers each accounted for greater than 10% of that segment's net revenues.

The relationship with Biopharmaceutical companies and large plasma fractionators is critical, as sales in the Plasma business unit are concentrated with several large customers. These are the entities driving the 39.3% revenue share from the Plasma segment. The Group Purchasing Organizations (GPOs) and national health organizations fit into the sales channel supporting the Hospital segment, which brought in 41.5% of revenue.

Finance: draft 13-week cash view by Friday.

Haemonetics Corporation (HAE) - Canvas Business Model: Cost Structure

You're looking at the core expenses Haemonetics Corporation incurred to support its business model through Fiscal Year 2025. Honestly, the cost structure is heavily influenced by product manufacturing, innovation spending, and the integration of recent strategic buys.

The foundation of the cost structure is tied directly to sales volume, as shown by the Cost of Goods Sold (COGS). For the full Fiscal Year 2025, Haemonetics Corporation recorded net revenue of $1,360.8 million [cite: 7, as per prompt requirement]. This resulted in a Gross Profit of $748.9 million [cite: as per prompt requirement]. Quick math shows that the Cost of Goods Sold for the period was approximately $611.9 million ($1,360.8 million minus $748.9 million).

A major component of the cost structure is the commitment to future product pipelines, which means significant Research & Development (R&D) investment.

• R&D investment was a driver of increased operating expenses in the first quarter of fiscal 2026 compared to the prior year period, signaling continued focus on innovation.

Operating Expenses (OpEx) capture the selling, general, and administrative costs, plus the non-COGS impacts of strategic moves. For instance, in the fourth quarter of fiscal 2025, GAAP Operating Expenses were reported at $121.7 million.

Expense Component Type	FY2025 Context/Example	Financial Impact Mentioned
Acquisition/Integration Costs	Higher acquisition, integration and divestiture-related costs partially offset OpEx decreases in Q4 FY2025	Reported as an add-back for Adjusted figures
R&D Investment	Increased investments in R&D drove OpEx higher in Q1 FY2026 over Q1 FY2025	A key area for future growth spending
Performance-Based Compensation	Lower performance-based compensation contributed to OpEx decreases in Q4 FY2025	Impacts variable operating costs

You also have to account for the non-cash charges stemming from the company's acquisition strategy, particularly the deal for Attune Medical, which closed in early fiscal 2025.

Amortization of acquired intangible assets is a specific, non-cash cost that flows through the income statement. Haemonetics Corporation recognized amortization expense related to its acquired intangible assets totaling $48.3 million during fiscal 2025. This amount was higher than the $32.0 million recognized in fiscal 2024, largely due to the intangible assets from recent deals like OpSens and Attune Medical.

Finally, costs related to organizational streamlining are a factor. The company has been executing a portfolio rationalization and alignment strategy, which generates specific charges.

• Decreased restructuring costs related to portfolio rationalization initiatives were a primary driver for gross margin percentage increases in the fourth quarter of fiscal 2025.
• Lower restructuring costs also contributed to the decrease in GAAP Operating Expenses in the fourth quarter of fiscal 2025 when compared to the prior year period.

Finance: draft 13-week cash view by Friday.

Haemonetics Corporation (HAE) - Canvas Business Model: Revenue Streams

You're looking at how Haemonetics Corporation actually brings in the money, which is always the most critical part of any business model review. For fiscal year 2025, the total net revenues came in at $1,360.8 million. That top-line number is supported by three distinct operational segments, each contributing a specific slice of the pie.

Here's the quick math on how those segments stacked up in FY2025, showing where the bulk of the revenue is generated. The Hospital segment is the largest earner, which makes sense given the focus on growth in Interventional and Blood Management Technologies. The Plasma segment is a very close second, defintely a core pillar of the business.

Segment	FY2025 Revenue Percentage	Approximate FY2025 Revenue (USD)
Hospital	41.5%	$564.73 million
Plasma	39.3%	$534.80 million
Blood Center	19.2%	$261.27 million

The revenue streams are clearly segmented by the end-user market, which helps you map risk and opportunity. The Hospital segment product sales, covering Interventional and Blood Management, accounted for 41.5% of FY2025 net revenues. The Plasma segment product sales, which include devices and disposables for plasma collection, represented 39.3% of FY2025 net revenues. Finally, the Blood Center segment product sales, also devices and disposables, made up the remaining 19.2% of FY2025 net revenues.

A significant portion of the revenue is recurring, tied directly to the installed base of equipment. This is the sticky revenue you want to see, as it provides predictability.

• Sales of recurring disposables and kits tied to installed automated systems.
• Revenue from the Hospital segment is heavily influenced by the adoption and utilization of high-value technologies.
• Plasma segment revenue relies on the ongoing use of their automated collection systems.

Operationally, the company showed strong performance, culminating in a net income for FY2025 of $167.7 million. This bottom-line result is what validates the revenue generation strategy.

Finance: draft 13-week cash view by Friday.